Midatech Pharma enrols first patient into Phase 1 Study of MTX-110

Midatech Pharma PLC (LON:MTPH; Nasdaq: MTP), an R&D biotechnology company focused on improving the bio-delivery and biodistribution of medicines, has announced the enrolment of the first patient into its Phase 1 study of MTX110 in recurrent glioblastoma (rGB) (NCT 05324501) at the Preston Robert Tisch Brain Tumor Center at Duke University, USA.

The Phase I study is an open-label, dose escalation study designed to assess the feasibility and safety of intermittent infusions of MTX110 administered by convection enhanced delivery (CED) via implanted refillable pump and catheter. The study aims to recruit two cohorts, each with a minimum of four patients; the first cohort will receive MTX110 only and the second cohort will receive MTX110 in combination with lomustine.

Midatech has previously reported encouraging results from a Phase I study of MTX110 in diffuse intrinsic pontine glioma (“DIPG”) conducted by University of California, San Francisco with an additional Phase I study of MTX110 in DIPG conducted by Columbia University expected to report shortly. In addition, a Phase I study of MTX110 in medulloblastoma is being undertaken at the University of Texas.

MTX110 has been granted Orphan Drug and Fast Track designations by the FDA and Orphan Medicinal Product designation by EMA.

Commenting, Annick Desjardins, MD, FRCPC, neuro-ongologist, professor of neurosurgery and neurology at Duke University and study’s principal investigator, said: “We are excited to be a leading center for the MAGIC-G1 study that is looking to overcome the limited penetration of panobinostat through the blood-brain barrier by its direct administration into the tumor, thus also potentially avoiding systemic toxicity.”

Commenting, Dmitry Zamoryakhin, MD, MBA, CSO of Midatech Pharma, said: “rGB is a devastating and incurable cancer marked by short survival rates and universal recurrence. A start of recruitment into the MAGIC-G1 study marks a significant step towards developing a potential new treatment paradigm for patients with this devastating disease that currently has limited effective treatment options.”

Sources:

(1) Low JT, Ostrom QT, Cioffi G, Neff C, Waite KA, Kruchko C, Barnholtz-Sloan JS. Primary brain and other central nervous system tumors in the United States (2014-2018): A summary of the CBTRUS statistical report for clinicians. Neurooncol Pract. 2022 Feb 22;9(3):165-182. doi: 10.1093/nop/npac015. PMID: 35601966; PMCID: PMC9113389.

(2) Stupp R, Taillibert S, Kanner AA, et al. Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial. JAMA : the journal of the American Medical Association. 2015;314(23):2535-2543.

Chinot OL, Wick W, Mason W, et al. Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma. N Engl J Med. 2014;370(8):709-722.

Click to view all articles for the EPIC:
Or click to view the full company profile:
    Share on facebook
    Facebook
    Share on twitter
    Twitter
    Share on linkedin
    LinkedIn
    Midatech pharma

    More articles like this

    Midatech pharma

    Midatech Pharma pleased with the progress made in H1 2022

    Midatech Pharma Plc (LON:MTPH; NASDAQ: MTP), a drug delivery technology company focused on improving the bio-delivery and biodistribution of medicines, has announced its unaudited interim results for the six months ended 30 June 2022 which will also be made

    Midatech pharma

    Midatech Pharma MTX110 study to be presented at ISPNO 2022

    Midatech Pharma PLC (LON:MTPH) an R&D biotechnology company focused on improving the bio-delivery and biodistribution of medicines, has announced that investigators from Columbia University Irving Medical Center and New York-Presbyterian will present interim results from their ongoing Phase 1

    Midatech pharma

    Midatech Pharma granted FDA Fast Track designation for MTX110

    Midatech Pharma PLC (LON:MTPH), an R&D biotechnology company focused on improving the bio-delivery and biodistribution of medicines, has announced that upon submitting an application to the U.S. Food and Drug Administration, its development programme of MTX110 for the treatment of

    Midatech pharma

    Midatech Pharma total gross revenue increases to £0.58m

    Midatech Pharma PLC (LON:MTPH), a drug delivery technology company focused on improving the bio-delivery and biodistribution of medicines, has announced its audited preliminary results for the year ended 31 December 2021. 2021 HIGHLIGHTS Operational · In June 2021, in an

    Midatech pharma

    Midatech Pharma extends R&D collaboration with Janssen

    Midatech Pharma PLC (LON:MTPH), a drug delivery technology company focused on improving the bio-delivery and biodistribution of medicines, has announced an extension of its existing R&D collaboration with Janssen Pharmaceutica NV originally announced on 21 July 2020. On 17

    Midatech pharma

    Midatech Pharma extends R&D collaboration with Janssen

    Midatech Pharma PLC (LON:MTPH; Nasdaq: MTP), a drug delivery technology company focused on improving the bio-delivery and biodistribution of medicines, has announced the extension of its R&D collaboration with Janssen Pharmaceutica NV originally announced on 21 July 2020. On

    Midatech pharma

    Midatech Pharma formally opens its new Cardiff headquarters

    Midatech Pharma PLC (LON:MTPH), a drug delivery technology company focused on improving the bio-delivery and biodistribution of medicines, has announced the formal opening today of its new headquarters, incorporating purpose built laboratory facilities and offices at 1 Caspian

    Midatech pharma

    Midatech Pharma investor webinar 10th September 2020

    Midatech Pharma plc (LON:MTPH ; Nasdaq: MTP), a drug delivery technology company focused on improving the bio-delivery and biodistribution of medicines, will be hosting an investor webinar at 2.00pm London time on the 10th September 2020, the day of